RaQualia Pharma Inc. revised earnings guidance for the full year ended December 31, 2020. For the full year, the company expects the net sale of JPY 1,579 million as compared to Previous forecast of JPY 2,192 million. Operating loss was JPY 260 million as compared to Previous forecasts of operating profit of JPY 70 million. Net loss attributable to owners of parents was JPY 333 million as compared to Previous forecasts of net profit of JPY 13 Million. Loss per share was JPY 15.93 compared to previous forecast of earnings per share of JPY 0.67.